Akamatsu, S., Kubota, M., Uozumi, R., Narita, S., Takahashi, M., Mitsuzuka, K., Hatakeyama, S., Sakurai, T., Kawamura, S., Ishidoya, S., Hoshi, S., Ishida, M., Mizuno, K., Ogura, K., Goto, T., Terada, N., Kobayashi, T., Yamasaki, T., Inoue, T., Tsuchiya, N., Ohyama, C., Arai, Y., Habuchi, T., Morita S, Ogawa, O. (2019) Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol. 2(3), 320-328.
Fujiyama, N., Satoh, S., Saito, M., Numakura, K., Inoue, T., Yamamoto, R., Saito, T., Nara, T., Kanda, S., Narita, S., Kagaya, H., Miura, M., Habuchi, T. (2019) Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation. Int Immunopharmacol. 76, 105881.
Fujiyama, N., Satoh, S., Saito, M., Numakura, K., Inoue, T., Yamamoto, R., Saito, T., Kanda, S., Narita, S., Mitobe, Y., Habuchi, T. (2019) Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study. Clin Exp Nephrol. 23(12), 1398-1406.
Hamano, I., Hatakeyama, S., Narita, S., Takahashi, M., Sakurai, T., Kawamura, S., Hoshi, S., Ishida, M., Kawaguchi, T., Ishidoya, S., Shimoda, J., Sato, H., Mitsuzuka, K., Tochigi, T., Tsuchiya, N., Arai, Y., Habuchi, T., Ohyama, C. (2019) Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol. 37(11), 2365-2373.
Kawahara T, Kojima T, Kandori S, Kurobe M, Yoshino T, Kimura T, Nagumo Y, Ishituka R, Mitsuzuka K, Narita S, Kobayashi T, Matsui Y, Ogawa O, Sugimoto M,Miyazaki J, Nishiyama H. (2019) TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. PLoS One. 14(8):e0220173.
Kodama, H., Hatakeyama, S., Narita, S., Takahashi, M., Sakurai, T., Kawamura, S., Hoshi, S., Ishida, M., Kawaguchi, T., Ishidoya, S., Shimoda, J., Narita, T., Sato, H., Mitsuzuka, K., Tochigi, T., Tsuchiya, N., Arai, Y., Habuchi, T., Ohyama, C. (2019) Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer. Clin Genitourin Cancer. 17(6), e1091-e1098.
Koizumi, A., Narita, S., Nakanishi, H., Ishikawa, M., Eguchi, S., Kimura, H., Takasuga, S., Huang, M., Inoue, T., Sasaki, J., Yoshioka, T., Habuchi, T., Sasaki, T. (2019) Increased fatty acyl saturation of phosphatidylinositol phosphates in prostate cancer progression. Sci Rep. 9(1), 13257.
Konishi, S., Hatakeyama, S., Numakura, K., Narita, S., Inoue, T., Saito, M., Tokui, N., Yamamoto, H., Yoneyama, T., Hashimoto, Y., Yoshikawa, K., Narita, S., Kawaguchi, T., Habuchi, T., Ohyama, C. (2019) Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. Clin Genitourin Cancer. 17(5), e1080-e1089.
Narita, S., Nomura, K., Hatakeyama, S., Takahashi, M., Sakurai, T., Kawamura, S., Hoshi, S., Ishida, M., Kawaguchi, T., Ishidoya, S., Shimoda, J., Sato, H., Mitsuzuka, K., Tochigi, T., Tsuchiya, N., Ohyama, C., Arai, Y., Nagashima, K., Habuchi, T. (2019) Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy. Cancer Med. 8(15), 6566-6577.
Narita, S., Nomura, K., Hatakeyama, S., Takahashi, M., Sakurai, T., Kawamura, S., Hoshi, S., Ishida, M., Kawaguchi, T., Ishidoya, S., Shimoda, J., Sato, H., Mitsuzuka, K., Tochigi, T., Tsuchiya, N., Ohyama, C., Arai, Y., Nagashima, K., Habuchi, T. (2019) Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Sci Rep. 9(1), 12071.
Narita, S., Nara, T., Kanda, S., Numakura, K., Saito, M., Inoue, T., Satoh, S., Nanjo, H., Tsuchiya, N., Mitsuzuka, K., Koie, T., Kawamura, S., Ohyama, C., Tochigi, T., Arai, Y., Habuchi, T. (2019) Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis. Clin Genitourin Cancer. 17(1), e113-e122.
Narita, S., Nara, T., Sato, H., Koizumi, A., Huang, M., Inoue, T., Habuchi, T. (2019) Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression. J Clin Med. 8(5). pii E597.
Numakura, K., Horikawa, Y., Kamada, S., Koizumi, A., Nara, T., Chiba, S., Kanda, S., Saito, M., Narita, S., Inoue, T., Shimoda, N., Habuchi, T. (2019) Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis. Mol Clin Oncol. 11(3), 320-324.
Numakura, K., Nara, T., Kanda, S., Saito, M., Narita, S., Inoue, T., Habuchi, T. (2019) Overweight Patients Less Improved Kidney Function After Laparoscopic Surgery for Adrenocortical Adenoma With Excess Cortisol Secretion. Front Endocrinol (Lausanne). (10), 572.
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G (2019) Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol 24:1089-1098.
Okamoto, T., Hatakeyama, S., Narita, S., Takahashi, M., Sakurai, T., Kawamura, S., Hoshi, S., Ishida, M., Kawaguchi, T., Ishidoya, S., Shimoda, J., Sato, H., Mitsuzuka, K., Tochigi, T., Tsuchiya, N., Arai, Y., Habuchi, T., Ohyama, C. (2019) Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan. World J Urol. 37(9), 1827-1835.
Raven PA, Lysakowski S, Tan Z, D'Costa NM, Moskalev I, Frees S, Struss W, Matsui Y, Narita S, Buttyan R, Chavez-Munoz C, So AI. (2019) Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer. J Cell Physiol. 234(11):20634-20647.
Shiota, M., Narita, S., Akamatsu, S., Fujimoto, N., Sumiyoshi, T., Fujiwara, M., Uchiumi, T., Habuchi, T., Ogawa, O., Eto, M. (2019) Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone. JAMA Netw Open. 2(2), e190115.
Terada, N., Kamoto, T., Tsukino, H., Mukai, S, Akamatsu, S., Inoue, T., Ogawa, O., Narita, S., Habuchi, T., Yamashita, S., Mitsuzuka, K., Arai, Y., Kandori, S., Kojima, T., Nishiyama, H., Kawamura, Y., Shimizu, Y., Terachi, T., Sugi, M., Kinoshita, H., Matsuda, T., Yamada, Y., Yamamoto, S., Hirama, H., Sugimoto, M., Kakehi, Y., Sakurai, T., Tsuchiya, N. (2019) The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. BMC Cancer. 19(1), 156.
Tomita, Y., Fukasawa, S., Shinohara, N., Kitamura, H., Oya, M., Eto, M., Tanabe, K., Saito, M., Kimura, G., Yonese, J., Yao, M., Uemura, H. (2019) Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. Jpn J Clin Oncol. 49(6):506-514.
Tomita, Y., Uemura, H., Oya, M., Shinohara, N., Habuchi, T., Fujii, Y., Kamei, Y., Umeyama ,Y., Bair, AH., Rini, BI. (2019) Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. BMC Cancer. 19(1), 17.
Iwamoto, H., Morizane, S., Koie, T., Shiroki, R., Kawakita, M., Gondo, T., Matsumoto, K., Habuchi, T., Sunada, H., Endo, Y., Noma, H., Takenaka, A., Kanayama, H. (2019) Peri-operative efficacy and long-term survival benefit of robotic-assisted radical cystectomy in septuagenarian patients compared with younger patients: a nationwide multi-institutional study in Japan. Int J Clin Oncol. 24(12), 1588-1595.